<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01124318</url>
  </required_header>
  <id_info>
    <org_study_id>04/09-AVVA RUS</org_study_id>
    <nct_id>NCT01124318</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Lactofiltrum to Treat Atopic Dermatitis in Adults</brief_title>
  <acronym>LF-AD-09</acronym>
  <official_title>Phase II Double Blind Placebo-controled Randomized Comparative Multicentered Study of Efficacy and Safety of Lactofiltrum, Orally Administered Tablets (Produced by AVVA RUS, JSC) to Treat Atopic Dermatitis in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avva Rus, JSC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Moscow State University of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moscow Dermatovenerologic Clinical Dispensary â„– 1</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Avva Rus, JSC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to study efficacy of Lactofiltrum in adult patients with atopic dermatitis.
      Lactofiltrum consists of 85% of hidrolytic lignin and 15% of lactulose and acts as an
      enterosorbent, which enables to enhance metabolism and elimination of endotoxins and to
      normalize metabolic and immune processes. Additionally, lactulose stimulates Bifidobacterium
      flora and in aggregate it could improve skin condition afflicted by atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SCORAD Index</measure>
    <time_frame>Day 21 after start of the intervention</time_frame>
    <description>The Scoring of Atopic Dermatitis (SCORAD) index is a composite index (0-100 scores) measured by blinded physician assessing three main clinical features of the disease (separate scales), namely area of lesion, clinical severity, subjective symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SCORAD Index</measure>
    <time_frame>Day 30 after end of the intervention</time_frame>
    <description>The Scoring of Atopic Dermatitis (SCORAD) index is a composite index (0-100 scores) measured by blinded physician assessing three main clinical features of the disease (separate scales), namely area of lesion, clinical severity, subjective symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCORAD Index</measure>
    <time_frame>Day 10 after start of the intervention</time_frame>
    <description>The Scoring of Atopic Dermatitis (SCORAD) index is a composite index (0-100 scores) measured by blinded physician assessing three main clinical features of the disease (separate scales), namely area of lesion, clinical severity, subjective symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatological Index of Life Quality</measure>
    <time_frame>Day 10 after start of the intervention</time_frame>
    <description>The Dermatological Index of Life Quality is a index (0-30 scores) representing patient's life quality deteriorations related to a skin disease (self-reported questionnaire).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatological Index of Life Quality</measure>
    <time_frame>Day 21 after start of the intervention</time_frame>
    <description>The Dermatological Index of Life Quality is a index (0-30 scores) representing patient's life quality deteriorations related to a skin disease (self-reported questionnaire).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatological Index of Life Quality</measure>
    <time_frame>Day 30 after end of the intervention</time_frame>
    <description>The Dermatological Index of Life Quality is a index (0-30 scores) representing patient's life quality deteriorations related to a skin disease (self-reported questionnaire).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BRS Index</measure>
    <time_frame>Day 10 after start of the intervention</time_frame>
    <description>Behavioral rating scores (BRS) measures severity of itching.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BRS Index</measure>
    <time_frame>Day 21 after start of the intervention</time_frame>
    <description>Behavioral rating scores (BRS) measures severity of itching.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BRS Index</measure>
    <time_frame>Day 30 after end of the intervention</time_frame>
    <description>Behavioral rating scores (BRS) measures severity of itching.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood test</measure>
    <time_frame>Day 21 after start of the intervention</time_frame>
    <description>It includes routine blood cells' counting and measurement of erythrocyte sedimentation rate and serum concentration of hemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical blood analysis</measure>
    <time_frame>Day 21 after start of the intervention</time_frame>
    <description>It includes routine measurements of serum concentrations of biochemical compounds including proteins, glucose, enzymes, creatinine, urea, potassium, sodium, bilirubin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine analysis</measure>
    <time_frame>Day 21 after start of the intervention</time_frame>
    <description>It includes routine measurements of urine concentrations of biochemical compounds including proteins and glucose, counting of cells, detection of bacteria and urinometry.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Lactofiltrum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactofiltrum</intervention_name>
    <description>Lactofiltrum (hydrolytic lignin 0.355, lactulose 0.12) 2 tablets three times a day before meals during 21 days</description>
    <arm_group_label>Lactofiltrum</arm_group_label>
    <other_name>Lactulose</other_name>
    <other_name>Lignin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 2 tablets 3 times a day before meals during 21 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients aged 18-60 y.o. diagnosed with atopic dermatitis according to the UK
             refinement of the Hanifin-Rajka diagnostic criteria;

          -  SCORAD Index more than 25.

        Exclusion Criteria:

          -  pregnancy and breast-feeding;

          -  severe diseases;

          -  concomitant infection diseases (including parasitic ones);

          -  diffusive connective-tissue (autoimmune) diseases;

          -  renal and hepatic failure;

          -  systemic or topical treatment with antibiotics, steroids, immunosuppressive,
             cytostatic or antimetabolite agents by the time of inclusion into the study;

          -  concomitant skin diseases: skin lymphoma, scab, lichen ruber planus, psoriasis;

          -  professional activity involving skin injury, exposure to cold, insolation, ultraviolet
             radiation;

          -  psychoses;

          -  application of pre-, probiotics, antibiotics, neuroleptics or tranquilizers 2 weeks
             before inclusion or during participation in the study;

          -  participation in other clinical study 1 month before inclusion or during participation
             in the proposed study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuriy Perlamutrov, MD, DrSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moscow State University of Medicine and Dentistry</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nickolay A. Kryuchkov, MD, PhD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Avva Rus, JSC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lyudmila Kobeleva, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Avva Rus, JSC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moscow Dermatovenerologic Clinical Dispensary â„– 1</name>
      <address>
        <city>Moscow</city>
        <zip>119071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow State University of Medicine and Dentistry</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2010</study_first_submitted>
  <study_first_submitted_qc>May 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2010</study_first_posted>
  <last_update_submitted>September 13, 2010</last_update_submitted>
  <last_update_submitted_qc>September 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Yuriy Perlamutrov, Head of dermatovenerologic diseases department</name_title>
    <organization>Moscow State University of Medicine and Dentistry</organization>
  </responsible_party>
  <keyword>Lactofiltrum</keyword>
  <keyword>atopic dermatitis</keyword>
  <keyword>itching</keyword>
  <keyword>Dermatological Index of Life Quality</keyword>
  <keyword>SCORAD</keyword>
  <keyword>Behavioral Rating Scores</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

